Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma

BACKGROUND: Chimeric antigen receptor T cell (CAR-T) therapy has achieved remarkable effects in refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL). However, many patients receiving CAR-T therapy still eventually die of disease recurrence or progression due to target antigen loss or exha...

Descripción completa

Detalles Bibliográficos
Autores principales: Ping, Nana, Qu, Changju, Li, Mengyun, Kang, Liqing, Kong, Danqin, Chen, Xiaochen, Wu, Qian, Xia, Fan, Yu, Lei, Yao, Hong, Yan, Lingzhi, Wu, Depei, Jin, Zhengming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011311/
https://www.ncbi.nlm.nih.gov/pubmed/35433994
http://dx.doi.org/10.21037/atm-22-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011311/
https://www.ncbi.nlm.nih.gov/pubmed/35433994
http://dx.doi.org/10.21037/atm-22-20

Ejemplares similares